Background: Heparin is used in the treatment of venous and arterial thromboembolic events, including unstable angina. Once unfractionated heparin is discontinued during the acute phase of unstable angina, it has been demonstrated that the disease process may be reactivated within hours. It is hypothesized that this reactivation may be a result of direct platelet activation by heparin that can linger even after the drug itself has been stopped. Prior studies have shown that heparin can either increase or decrease platelet activation. More recent studies have also shown conflicting effects of unfractionated heparin on PFA-100 testing.
Methods: We studied the in-vitro effects of unfractionated heparin on platelet function and PFA-100 testing. Unfractionated heparin was incubated with whole blood taken from 18 healthy volunteers. Platelet activation and aggregation was assessed with and without the presence of heparin.
Results: Platelet aggregation and activation were increased in the presence of heparin. Unfractionated heparin also significantly prolonged collagen/adenosine diphosphate closure time but did not affect collagen/epinephrine closure time.
Conclusions: Unfractionated heparin leads to direct platelet activation and increases platelet aggregation in vitro. Unfractionated heparin causes prolongation of the collagen/adenosine diphosphate closure time in PFA-100 testing, possibly as a result of direct binding to von Willebrand factor in solution and interference with von Willebrand factor-glycoprotein Ib binding.
John LC , Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg105:816-822, 1993
2.
Khuri SF , Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg60:1008-1014, 1995
3.
Salzman EW , Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest65:64-73, 1980
4.
Mascelli MA , Kleiman NS, Marciniak SJ Jr, et al. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J139:696-703, 2000
5.
Thomson C , Forbes CD, Prentice CR. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med45:485-494, 1973
6.
Ellison N , Edmunds LH Jr, Colman RW. Platelet aggregation following heparin and protamine administration. Anesthesiology48:65-68, 1978
7.
Horne MK 3rd , Chao ES. Heparin binding to resting and activated platelets. Blood74:238-243, 1989
8.
Theroux P , Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med319:1105-1111, 1988
9.
Theroux P , Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation88(5 Pt 1):2045-2048, 1993
10.
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease . the RISC Group. Lancet336:827-830, 1990
11.
Theroux P , Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med327:141-145, 1992
12.
Kundu SK , Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer—PFA-100. Semin Thromb Hemost21 Suppl2:106-112, 1995
13.
Mammen EF , Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost21 Suppl2:113-121, 1995
14.
Mammen EF , Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost24:195-202, 1998
15.
Kottke-Marchant K , Powers JB, Brooks L, et al. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost5:122-130, 1999
16.
Peters AJ , Borries M, Gradaus F, et al. In vitro bleeding test with PFA-100—aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis12:263-272, 2001
17.
Slaughter TF , Sreeram G, Sharma AD, et al. Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis12:85-93, 2001
18.
Shattil S , Cunningham M, Hoxie J. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood70:307-315, 1987
19.
Rosenberg RD BK . Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed.Philadelphia, PA: JB Lippincott Co; 1994
20.
Ofosu FA , Sie P, Modi GJ, et al. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J243:579-588, 1987
21.
Eika C . On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol9:248-257, 1972
22.
Holmer E , Lindahl U, Backstrom G, et al. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res18:861-869, 1980
23.
Xiao Z , Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation97:251-256, 1998
24.
Sobel M , McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest87:1787-1793, 1991
